We are also using physician education campaigns to help expand the market for the Enteryx procedure, our new endoscopic therapy for the treatment of symptoms related to gastroesophageal reflux disease (GERD), or acid reflux disease. Our ultimate goal for the U.S. is to train 4,500 endoscopists in this injectible, less-invasive treatment, bringing the possibility of relief to many of the estimated 15 million people with GERD in the U.S. alone.

Patient education – providing patients with the information necessary to advocate for themselves – is another element of our development strategy. We have established a relationship with Body1, a developer of patient education websites, to create online resources for patients. These websites provide detailed and objective information about current treatment options for a broad range of illnesses and conditions. Sites we have sponsored to date include www.fibroids1.com, providing information for uterine fibroids patients, www.uterus1.com, for patients with abnormal uterine bleeding, and www.reflux1.com, for GERD patients. We are also exploring patient outreach opportunities – including additional specialized websites – in a number of other areas.

As the company continues to grow and patients become more sophisticated health care consumers, we will use our knowledge leadership position to take advantage of additional growth opportunities in patient education and physician education and training, as well as opportunities in the area of direct-to-consumer outreach.